리시노프릴

용도

• Adjunctive treatment of heart failure
• Adjunctive treatment of heart failure
• Adjunctive treatment of heart failure
• Adjunctive treatment of heart failure

투여 방법

가능한 부작용

• Anorexia
• Vomiting
• Diarrhea
• Lethargy or weakness
• Hypotension
• Renal dysfunction (azotemia)
• Hyperkalemia
• Cough (rare in animals compared to humans)

주의사항 및 금기

• Known hypersensitivity to ACE inhibitors
• Pregnancy (especially 2nd and 3rd trimesters)
• Use with caution and close supervision in patients with **renal insufficiency** (doses may need to be reduced). Use cautiously in patients with **hyponatremia** or sodium depletion, coronary or cerebrovascular insufficiency, preexisting hematologic abnormalities, or collagen vascular diseases (e.g., SLE). Patients with severe CHF should be monitored very closely for hypotension upon initiation of therapy. May cause a reversible decrease in localization and excretion of certain renal imaging agents.

약물 상호작용

• Antidiabetic Agents (insulin, oral agents): Possible increased risk for hypoglycemia; enhanced monitoring recommended.
• Diuretics (e.g., furosemide, hydrochlorothiazide): Potential for increased hypotensive effects; reducing furosemide doses (by 25-50%) is often recommended when initiating ACE inhibitors in CHF.
• Potassium-Sparing Diuretics (e.g., spironolactone, triamterene): Increased risk of hyperkalemia; enhanced monitoring of serum potassium recommended.
• Other Hypotensive Agents: Potential for additive hypotensive effects.
• Lithium: Increased serum lithium levels possible; increased monitoring required.
• NSAIDs: May reduce the anti-hypertensive or positive hemodynamic effects of lisinopril; may increase the risk of acute renal failure.
• Potassium Supplements: Increased risk for hyperkalemia.

자주 묻는 질문